Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 Clinical Trial
Official title:
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, HPV-Negative Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
PRIMARY OBJECTIVES:
I. To select the better docetaxel-based experimental arm to improve disease-free survival
(DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF
20-MAR-2020) II. To determine if the combination of docetaxel-cetuximab and
intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS)
compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk,
human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). (Phase
III) III. To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in
terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic
high risk, HPV-negative HNSCC. (Phase III)
SECONDARY OBJECTIVES:
I. To compare disease-free survival (DFS) between each experimental arm and the control arm.
(Phase III) II. To determine whether each experimental arm improves local-regional disease
control and the rate of distant metastasis. (Phase III) III. To compare acute toxicity
profiles between each experimental arm and the control arm. (Phase III) IV. To compare late
toxicity profiles at 1, 3, and 5 years after treatment. (Phase III) V. To assess long term
DFS and OS between each experimental arm and the control arm. (Phase III)
EXPLORATORY OBJECTIVE:
I. To collect blood and tissue specimens for future translational research. (Phase III)
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM 1: Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) five
days a week for 6 weeks and receive concurrent cisplatin intravenously (IV) over 1-2 hours
once weekly for 6 weeks.
ARM 2: Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes
once weekly for 6 weeks. (CLOSED AS OF 20-MAR-2020)
ARM 3: Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once
weekly on weeks 2-7. Patients undergo IMRT as in Arm I and concurrent receive docetaxel once
weekly for 6 weeks.
ARM 4: Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin
IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive
atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12,
15, 18, and 21) in the absence of disease progression and unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 3 months, every 3
months for 2 years, every 6 months for 3 years, and then annually thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02381535 -
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
|
Phase 1 | |
| Active, not recruiting |
NCT03468218 -
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
|
Phase 2 | |
| Completed |
NCT02775812 -
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Terminated |
NCT02917629 -
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
|
Phase 2 | |
| Terminated |
NCT03601507 -
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03799445 -
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT03144778 -
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
|
Phase 1 | |
| Completed |
NCT01064479 -
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Completed |
NCT01254617 -
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00588770 -
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01893307 -
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT01935921 -
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02567422 -
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
|
Phase 1 |